{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:06:17Z","timestamp":1780967177257,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1175929"],"award-info":[{"award-number":["APP1175929"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40266-024-01095-z","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T15:03:47Z","timestamp":1709737427000},"page":"271-281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-1577","authenticated-orcid":false,"given":"Luke S.","family":"McLean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette M.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesha A.","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"issue":"6","key":"1095_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1095_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13014-021-01832-3","volume":"16","author":"E Haehl","year":"2021","unstructured":"Haehl E, R\u00fchle A, Klink R, Kalckreuth T, Sprave T, Gkika E, et al. The value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly. Radiat Oncol. 2021;16(1):105.","journal-title":"Radiat Oncol"},{"key":"1095_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2023.01.017","volume":"183","author":"U Keim","year":"2023","unstructured":"Keim U, Katalinic A, Holleczek B, Wakkee M, Garbe C, Leiter U. Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland. Eur J Cancer. 2023;183:60\u20138.","journal-title":"Eur J Cancer"},{"issue":"22","key":"1095_CR4","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.3390\/cancers13225645","volume":"13","author":"AA Thai","year":"2021","unstructured":"Thai AA, Lim AM, Solomon BJ, Rischin D. Biology and treatment advances in cutaneous squamous cell carcinoma. Cancers (Basel). 2021;13(22):5645.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1095_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1095_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"1095_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000775","volume":"8","author":"D Rischin","year":"2020","unstructured":"Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020;8(1): e000775.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"1095_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002757","volume":"9","author":"D Rischin","year":"2021","unstructured":"Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021;9(8): e002757.","journal-title":"J Immunother Cancer"},{"issue":"25","key":"1095_CR9","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.03054","volume":"38","author":"JJ Grob","year":"2020","unstructured":"Grob JJ, Gonzalez R, Basset-Seguin N, Vornicova O, Schachter J, Joshi A, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J Clin Oncol. 2020;38(25):2916\u201325.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1095_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jgo.2019.07.017","volume":"11","author":"MS Sedrak","year":"2020","unstructured":"Sedrak MS, Mohile SG, Sun V, Sun CL, Chen BT, Li D, et al. Barriers to clinical trial enrollment of older adults with cancer: a qualitative study of the perceptions of community and academic oncologists. J Geriatr Oncol. 2020;11(2):327\u201334.","journal-title":"J Geriatr Oncol"},{"issue":"12","key":"1095_CR11","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","volume":"7","author":"CA Nebhan","year":"2021","unstructured":"Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, et al. Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study. JAMA Oncol. 2021;7(12):1856\u201361.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1095_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1053\/j.seminoncol.2003.12.024","volume":"31","author":"R Yancik","year":"2004","unstructured":"Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31(2):128\u201336.","journal-title":"Semin Oncol"},{"issue":"2","key":"1095_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/ncponc0420","volume":"3","author":"SM Lichtman","year":"2006","unstructured":"Lichtman SM. Therapy insight: therapeutic challenges in the treatment of elderly cancer patients. Nat Clin Pract Oncol. 2006;3(2):86\u201393.","journal-title":"Nat Clin Pract Oncol"},{"issue":"14","key":"1095_CR14","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.3390\/cancers13143547","volume":"13","author":"C Hober","year":"2021","unstructured":"Hober C, Fredeau L, Pham-Ledard A, Boubaya M, Herms F, Celerier P, et al. Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: real-life experience from the French CAREPI study group. Cancers (Basel). 2021;13(14):3547.","journal-title":"Cancers (Basel)"},{"key":"1095_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","volume":"157","author":"A Baggi","year":"2021","unstructured":"Baggi A, Quaglino P, Rubatto M, Depenni R, Guida M, Ascierto PA, et al. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Eur J Cancer. 2021;157:250\u20138.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1095_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252925","volume":"16","author":"M Salas","year":"2021","unstructured":"Salas M, Henderson M, Sundararajan M, Tu N, Islam Z, Ebeid M, et al. Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: a systematic review. PLoS ONE. 2021;16(6): e0252925.","journal-title":"PLoS ONE"},{"issue":"1","key":"1095_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12890-017-0452-0","volume":"17","author":"L Zhao","year":"2017","unstructured":"Zhao L, Leung L-H, Wang J, Li H, Che J, Liu L, et al. Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. BMC Pulm Med. 2017;17(1):112.","journal-title":"BMC Pulm Med"},{"issue":"5","key":"1095_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jgo.2021.02.002","volume":"12","author":"AC Johns","year":"2021","unstructured":"Johns AC, Wei L, Grogan M, Hoyd R, Bridges JFP, Patel SH, et al. Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. J Geriatr Oncol. 2021;12(5):813\u20139.","journal-title":"J Geriatr Oncol"},{"key":"1095_CR19","unstructured":"World Health Organization. WHO handbook for reporting results of cancer treatment (WHO Offset Publication no 48). Geneva: WHO, 1979. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/37200\/WHO_OFFSET_48.pdf?sequence=1&isAllowed=y. Accessed Oct 2023."},{"issue":"Suppl 1","key":"1095_CR20","doi-asserted-by":"publisher","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122s\u201350s.","journal-title":"J Nucl Med."},{"issue":"25","key":"1095_CR21","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","volume":"29","author":"E Maubec","year":"2011","unstructured":"Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419\u201326.","journal-title":"J Clin Oncol"},{"key":"1095_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686308","volume":"11","author":"S Strippoli","year":"2021","unstructured":"Strippoli S, Fanizzi A, Quaresmini D, Nardone A, Armenio A, Figliuolo F, et al. Cemiplimab in an elderly frail population of patients with locally advanced or metastatic cutaneous squamous cell carcinoma: a single-center real-life experience from Italy. Front Oncol. 2021;11: 686308.","journal-title":"Front Oncol"},{"issue":"17","key":"1095_CR23","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.3390\/cancers15174312","volume":"15","author":"EC Koch Hein","year":"2023","unstructured":"Koch Hein EC, Vilbert M, Hirsch I, Fernando Ribeiro M, Muniz TP, Fournier C, et al. Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: real-world experience from a Canadian Comprehensive Cancer Centre. Cancers (Basel). 2023;15(17):4312.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1095_CR24","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1200\/JOP.2014.001457","volume":"10","author":"RW Jang","year":"2014","unstructured":"Jang RW, Caraiscos VB, Swami N, Banerjee S, Mak E, Kaya E, et al. Simple prognostic model for patients with advanced cancer based on performance status. J Oncol Pract. 2014;10(5):e335\u201341.","journal-title":"J Oncol Pract"},{"issue":"11","key":"1095_CR25","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.21037\/jtd-2019-cptn-10","volume":"12","author":"S Rakshit","year":"2020","unstructured":"Rakshit S, Molina JR. Immunotherapy in patients with autoimmune disease. J Thorac Dis. 2020;12(11):7032\u20138.","journal-title":"J Thorac Dis"},{"issue":"3","key":"1095_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0895-4356(02)00585-1","volume":"56","author":"V de Groot","year":"2003","unstructured":"de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol. 2003;56(3):221\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"1095_CR27","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/MLR.0b013e31825f64d0","volume":"50","author":"MT Sharabiani","year":"2012","unstructured":"Sharabiani MT, Aylin P, Bottle A. Systematic review of comorbidity indices for administrative data. Med Care. 2012;50(12):1109\u201318.","journal-title":"Med Care"},{"issue":"1","key":"1095_CR28","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1038\/s41598-019-44969-8","volume":"9","author":"ML Pule","year":"2019","unstructured":"Pule ML, Buckley E, Niyonsenga T, Roder D. The effects of comorbidity on colorectal cancer mortality in an Australian cancer population. Sci Rep. 2019;9(1):8580.","journal-title":"Sci Rep"},{"issue":"6","key":"1095_CR29","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/hed.23360","volume":"36","author":"S Habbous","year":"2014","unstructured":"Habbous S, Harland LT, La Delfa A, Fadhel E, Xu W, Liu FF, et al. Comorbidity and prognosis in head and neck cancers: differences by subsite, stage, and human papillomavirus status. Head Neck. 2014;36(6):802\u201310.","journal-title":"Head Neck"},{"issue":"1","key":"1095_CR30","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1634\/theoncologist.2019-0241","volume":"25","author":"F Retornaz","year":"2020","unstructured":"Retornaz F, Guillem O, Rousseau F, Morvan F, Rinaldi Y, Nahon S, et al. Predicting chemotherapy toxicity and death in older adults with colon cancer: results of MOST study. Oncologist. 2020;25(1):e85\u201393.","journal-title":"Oncologist"},{"key":"1095_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.796197","volume":"11","author":"LS McLean","year":"2021","unstructured":"McLean LS, Lim AM, Webb A, Cavanagh K, Thai A, Magarey M, et al. Immunotherapy to avoid orbital exenteration in patients with cutaneous squamous cell carcinoma. Front Oncol. 2021;11: 796197.","journal-title":"Front Oncol"},{"key":"1095_CR32","unstructured":"Majeed H, Gupta V. Adverse Effects of Radiation Therapy 2023 [Available from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563259\/.]"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01095-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-024-01095-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01095-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T20:52:07Z","timestamp":1710363127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-024-01095-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1007\/s40266-024-01095-z","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"30 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. This study was funded by an NHMRC Investigator Grant (APP1175929) held by Danny Rischin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Author Luke S. Mclean has received speaker honorarium and conference registration support from Sanofi and travel support\/conference registration support from Merck, Sharpe & Dohme. Author Annette M. Lim provides uncompensated consultancy for Eisai and receives salary support from a Peter MacCallum Cancer Centre Discovery Partner Fellowship and institutional support from Sanofi\/Regeneron Pharmaceuticals. Author Alesha A. Thai has received honorarium and is an advisory board member with BMS, Merck, La Roche Posay, and Akesobio. Author Danny Rischin is a member of trial steering committees and\/or advisory boards (all uncompensated)\u2014MSD, GSK, Regeneron, and Sanofi. He receives institutional trial funding from Merck Sharp & Dohme, Decibel Therapeutics, Bristol-Myers Squibb, GSK, Roche, Regeneron, Kura Oncology, and ALX Oncology. Author Mathias Bressel has no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This retrospective study was approved by the Human Research Ethics Committee (HREC) (HREC\/68865\/PMCC) of the Peter MacCallum Cancer Centre, Melbourne, Australia, with a waiver for patient consent granted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval\/Consent to Participate\/Consent to Publication"}},{"value":"The datasets generated during and\/or analysed during the current study are not authorised to be publicly available under the current ethics approval. However, any queries regarding the datasets generated and analysed for this project may be directed to the corresponding author.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Any queries regarding the code used for the analyses in this study may be directed to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Authors LSM, AML, AAT, and DR contributed to the study concept and design. LSM and MB contributed to the data collection and analysis. The first draft of the manuscript was written by LSM. All authors commented on previous versions of the manuscript and read and approved the final version.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}